Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.

@article{Foster2015EfficacyOS,
  title={Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.},
  author={Graham R Foster and Stephen Pianko and Ashley S. Brown and Daniel M Forton and Ronald G. Nahass and Jacob George and Eleanor Barnes and Diana M. Brainard and Benedetta Massetto and Ming-hua Lin and Bin Han and John McHutchison and Gangadharan Mani Subramanian and Curtis L. Cooper and Kosh Agarwal},
  journal={Gastroenterology},
  year={2015},
  volume={149 6},
  pages={
          1462-70
        }
}
BACKGROUND & AIMS We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naïve or treatment-experienced patients with HCV genotype 3 infection. METHODS The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to… 

Figures and Tables from this paper

Efficacy of Sofosbuvir plus Ribavirin in Treatment-Naive Patients with Genotype-1 and -3 HCV Infection: Results from a Russian Phase IIIb Study

Sofosbuvir plus ribavirin was safe and well tolerated regardless of treatment duration, and the presence of the L159F resistance-associated variant at baseline was associated with a high SVR rate in patients with HCV genotype-3.

Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success?

  • F. Sáez‐royuelaE. Badía
  • Medicine
    Liver international : official journal of the International Association for the Study of the Liver
  • 2016
Results indicate that patients with cirrhosis may benefit from more than 12 weeks of therapy with the discovery and development of DAA against genotype 2 hepatitis C virus (HCV) therapies.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.

Sofosbuvir plus ribavirin in treatment‐naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India

Overall, sofosbuvir plus ribavirin therapy achieved SVR12 rates ≥90% and was well tolerated among treatment‐naïve patients with chronic genotype 1 or 3 HCV infection in India.

Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice

The sofosbuvir and ribavirin combination is safe and effective in treatment of HCV patients with liver cirrhosis, however, further studies are needed to establish the optimal treatment regimen for those cases.

Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial

Data from this study support the use of EBR/GZR plus SOF for 12 weeks without RBV for treatment-naive and peginterferon/RBV-experienced people with GT3 infection and cirrhosis.

SOFOSBUVIR AND RIBAVIRIN ; RESPONSE TO 16-WEEKS VERSUS 24-WEEKS DUAL THERAPY INCLUDING SOFOSBUVIR AND RIBAVIRIN , IN ALL CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE-3 A INFECTION IN POPULATION OF KPK-PAKISTAN

Results of this study confirm that dual therapy given for 24-weeks is more effective compare to 16-the authors weeks therapy in both treatment naïve and previously non-responder cases, with chronic hepatitis-C genotype-3a infections.

Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study

Both dual and triple therapy regimes resulted in SVR rates of >95% in CHC genotype 3 who were naive non-cirrhotics, however, theSVR rates were low in treatment-experienced cirrhotic patients, and common adverse events were fatigue, headache, and myalgia.

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial

Data from this study support the use of EBR/GZR plus SOF for 12 weeks without RBV for treatment‐naive and peginterferon/RBV–experienced people with GT3 infection and cirrhosis.
...

References

SHOWING 1-10 OF 18 REFERENCES

Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.

Current guidelines do not recommend the use of ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 3 infection.

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

In treatment‐experienced patients with HCV genotypes 2 and 3, 12‐week administration of SOF+Peg‐IFN+RBV provided high SVR rates, irrespective of cirrhosis status, and no safety concerns were identified.

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 weeks of treatment with sofosbuvir and ribvirin was effective.

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Therapy with sofosbuvir-ribavirin for 12 weeks in patients with hepatitis C virus genotype 2 infection and for 24 weeks in Patients with HCV genotype 3 infection resulted in high rates of sustained virologic response.

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

A 12‐week regimen of DCV plus SOF achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis and was well tolerated; there were no adverse events leading to discontinuation and only 1 serious AE on‐treatment, which was unrelated to study medications.

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.

  • A. YauE. Yoshida
  • Biology, Medicine
    Canadian journal of gastroenterology & hepatology
  • 2014
The optimal all-oral interferon-free antiviral regimen likely entails a combination of an NS5B nucleotide polymerase inhibitor with either a second-generation NS3/4A protease inhibitor or an NS 5A replication complex inhibitor with or without RBV.

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

These data demonstrate a uniform susceptibility of subject-derived HCV to sofosbuvir, and show that selection of sofOSbuvir-resistant HCV is exceedingly rare and is associated with a significant reduction in viral fitness.

Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C

The transition of HCV therapeutics from an interferon-α based combination therapy to an all-oral, directly acting antiviral therapy is reported.

Treatment of hepatitis C in liver transplant patients: Interferon out, direct antiviral combos in

  • J. PriceN. Terrault
  • Medicine, Biology
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2015
The experience to date with treating HCV in the setting of cirrhosis and liver transplantation is reviewed and the unique challenges encountered when this population of patients is being treated are discussed.

Is genotype 3 of the hepatitis C virus the new villain?

Increasing clinical and experimental data show that HCV genotype 3 may be associated not only with severe steatosis, but also with accelerated fibrosis progression rate and increased oncogenesis, suggesting better and more potent, genotype‐targeted treatments.